Sugi Predict

Sugi Predict / Compounds / SCHEMBL2238055

SCHEMBL2238055

SCHEMBL2238055

CC(=O)NCCCC(N)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OTC P00480 1/20 0.57
▸ KDM4E B2RXH2 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ HIF1A Q16665 1/20 0.52
▸ NOS2 P35228 5/20 0.50
▸ NOS1 P29475 4/20 0.50
▸ NOS3 P29474 3/20 0.50
▸ GSR P00390 1/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ KMT2A Q03164 1/20 0.50
▸ DDAH1 O94760 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ PAOX Q6QHF9 2/20 0.48
▸ BLM P54132 1/20 0.47
▸ ADRA1A P35348 1/20 0.47
▸ DPP7 Q9UHL4 1/20 0.46
▸ ARG1 P05089 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3503365 1.00 OTC (0.57) OTCKDM4EMAPK1HIF1ANOS2
SCHEMBL976174 1.00 OTC (0.57) OTCKDM4EMAPK1HIF1ANOS2
SCHEMBL236178 0.94 KDM4E (0.56) OTCKDM4EMAPK1HIF1ANOS2
SCHEMBL180969 0.94 KDM4E (0.56) OTCKDM4EMAPK1HIF1ANOS2
SCHEMBL919222 0.94 KDM4E (0.56) OTCKDM4EMAPK1HIF1ANOS2
Hydrochloric Acid SCHEMBL15669798 0.92 KDM4E (0.54) OTCKDM4EMAPK1HIF1ANOS2
SCHEMBL30125060 0.92 KDM4E (0.59) OTCKDM4EMAPK1HIF1ANOS2
Hydrochloric Acid SCHEMBL28854969 0.92 KDM4E (0.54) OTCKDM4EMAPK1HIF1ANOS2
Ethylene SCHEMBL28796155 0.91 KDM4E (0.52) OTCKDM4EMAPK1HIF1ANOS2
Lysine SCHEMBL20898428 0.88 GSR (0.67) OTCKDM4EMAPK1HIF1ANOS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025100520-A1 PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE ペプチドリーム株式会社 2025-05-15 — — WO claimed
EP-3967703-B1 CYCLIC PEPTIDE, CELL SCAFFOLD MATERIAL, CELL SEPARATION MATERIAL AND CULTURE MEDIUM FUJIFILM CORP (JP) 2023-07-26 — — EP claimed
WO-2022080385-A1 PEPTIDE, AND MODIFICATION OF ANTIBODY WITH PEPTIDE 国立大学法人京都大学 2022-04-21 — — WO claimed
US-10316010-B2 Versatile non-destructive surface modification of carbonaceous materials and process for grafting into polymer matrices SOUTH DAKOTA BOARD OF REGENTS (US) 2019-06-11 — — US claimed
WO-2025100520-A1 PEPTIDE, PEPTIDE COMPLEX, PHARMACEUTICAL COMPOSITION, COMPOSITION FOR CELL CULTURE, AND COMPOSITION FOR MEDICAL USE, DIAGNOSTIC USE, OR RESEARCH USE ペプチドリーム株式会社 2025-05-15 — — WO disclosed
US-12209252-B2 Transduction buffer KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) 2025-01-28 — — US disclosed
US-20240285785-A1 TARGETING SORTILIN PROTEINQURE INC. (CA) 2024-08-29 — — US disclosed
EP-3954390-B1 TRANSDUCTION BUFFER KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) 2024-08-07 — — EP disclosed
US-20240150801-A1 MUTANT OF CORYNEBACTERIUM GLUTAMICUM WITH ENHANCED L-CITRULLINE PRODUCTIVITY AND METHOD FOR PREPARING L-CITRULLINE USING THE SAME DAESANG CORPORATION (KR) 2024-05-09 — — US disclosed
CN-117887800-A Screening of amino acid composite bactericide and safe disinfection and sterilization of space, surface, skin and the like 天津市天大天福生物技术有限公司 2024-04-16 — — CN disclosed
US-11939588-B2 Elevated resistance to insects and plant pathogens without compromising seed production BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) 2024-03-26 — — US disclosed
CN-116270849-B Preparation method of plaster for treating cancer pain 湖南省中医药研究院附属医院 2024-01-26 — — CN disclosed
US-20130225506-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY POLYPHOR AG (CH) 2013-08-29 — — US disclosed
WO-2013050346-A1 TEMPLATE -FIXED PEPTIDOMIMETICS AS INHIBITORS OF FPR1 POLYPHOR AG (CH) 2013-04-11 — — WO disclosed
US-8383887-B2 Methods of using plants containing the gdhA gene SOUTHERN ILLINOIS UNIVERSITY CARBONDALE (US) 2013-02-26 — — US disclosed
EP-2531520-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY Polyphor AG (CH) 2012-12-12 — — EP disclosed
US-20120041183-A1 CELLULOSE MATERIALS WITH NOVEL PROPERTIES FPINNOVATIONS (CA) 2012-02-16 — — US disclosed
WO-2011095607-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY POLYPHOR AG (CH) 2011-08-11 — — WO disclosed
WO-2011095218-A1 TEMPLATE-FIXED PEP TIDOMIME TICS WITH CXCR7 MODULATING ACTIVITY POLYPHOR AG (CH) 2011-08-11 — — WO disclosed
US-20100223693-A1 METHODS OF USING PLANTS CONTAINING THE GDHA GENE SOUTHERN ILLINOIS UNIVERSITY CARBONDALE (US) 2010-09-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240285785-A1 TARGETING SORTILIN SORT1, SCARB1, SELPLG OTC 4309/4885KDM4E 4679/4885MAPK1 4323/4885
US-20130225506-A1 TEMPLATE-FIXED PEPTIDOMIMETICS WITH CXCR7 MODULATING ACTIVITY CXCR1, CXCL12, CXCR6 OTC 3134/4885KDM4E 4606/4885MAPK1 2334/4885
US-12209252-B2 Transduction buffer STAT3, JAK2, CFTR OTC 652/4885KDM4E 4597/4885MAPK1 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.